There is no cure for Prader-Willi syndrome (PWS). It is caused by missing genes on chromosome 15 that affect the hypothalamus, the brain's appetite and hormone center, so people feel constant, extreme hunger. On March 26, 2025 the FDA approved Vykat XR (diazoxide choline) for hyperphagia, the first drug for it, in people 4 and older. Growth hormone, strict food-environment control and therapy remain the base of care. Our view: the cure will need to restore the silent genes, which is still lab-stage. Until then, controlling hunger and protecting health is where the progress is.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with a PWS-experienced medical team.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your PWS-experienced care team.
Switching off Snord116 in the appetite center of adult mice made them overeat weeks later (J Clin Invest, 2018), so these genes may be needed all through life, not only as the brain forms. Could waking the mother's copy in that same small region, after extreme hunger has set in, reduce it? The test would be in animals that already overeat.
What would prove it wrong: if waking these genes in the appetite center of animals that already overeat leaves their eating unchanged.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
A case report followed one boy with PWS for 3 years on an energy-restricted diet with set meal times, portion control, family supervision and exercise. Weight and metabolic markers improved at first, then weight rose again around puberty, after slower growth and less sticking to the plan following a school change. The authors say nutrition needs ongoing monitoring that fits each stage of development. One child, so it shows no general result.
A review checked PWS against Australia's newborn screening criteria. It says new blood-spot tests are accurate and early diagnosis could allow earlier growth hormone, diet and behavior support. It also notes there is no cost-effectiveness data yet and no cure. A review, not a new trial.
A review argues that changes in the brain messengers serotonin, dopamine and norepinephrine may help explain hunger, mood, behavior and sleep problems in PWS. It notes that medicines acting on these messengers help some symptoms in some people but vary widely, and some people become more agitated. A review of existing evidence, not a new trial or treatment.
Experts reviewed trials of oxytocin, GLP-1 drugs and diazoxide choline. They conclude that controlled access to food is crucial, that oxytocin in infants was linked to less severe hunger at ages 3 and 4, and that GLP-1 drugs seem to give only modest weight effects. Diazoxide choline, the first approved hunger treatment, showed promising results, but food control is still needed. A review, not a new trial.
STAT reports that Karen Vogt, a pediatric endocrinologist and former FDA medical officer, is urging the FDA to withdraw Vykat XR. Case reports obtained through a public-records request describe seven deaths and nearly 100 hospitalizations. These reports do not prove the drug caused them, and many involved complex medical problems and other medicines. Families should not stop or change the drug without talking to their care team. (Most of the article is behind a paywall; the FDA and company responses were not readable.)
Researchers found that a protein called SMCHD1 keeps the silenced maternal copy of the Prader-Willi gene region turned off. Removing it after early development switched those genes on in mouse brain areas such as the hypothalamus and improved features in a PWS mouse model, with no obvious harm. This is lab and mouse work, not a human treatment.
73% of the 30 people (ages 3 to 45) had at least one parent-reported mental health condition; anxiety (65%), obsessive-compulsive disorder (43%) and depression (40%) were most common. Those with a condition also had more autistic traits and food-seeking behavior. Small study based on parent reports; it points to a need for earlier support.
In 59 young males with PWS (44 on testosterone), challenging-behavior scores did not change significantly. Three (6.8%) stopped testosterone because of behavior problems. Bone density held steady and lean body mass improved. This was an observational study without a placebo group, and the authors stress close monitoring.
Neurocrine announced it will present posters and talks at the Foundation for Prader-Willi Research symposium in Philadelphia, including long-term hyperphagia results, safety analyses, and real-world use of GLP-1 drugs. These are announcements of upcoming presentations, not results yet.
The Foundation for Prader-Willi Research and the International Prader-Willi Syndrome Organisation issued a joint statement about after-approval reports of serious problems such as swelling (edema), breathing and heart complications. The FDA adverse-event database showed seven death reports as of July 31. The groups said the reports do not show cause and effect. Neurocrine said the drug has a favorable risk-benefit profile, and an HHS spokesperson said the FDA is evaluating the data.
In a randomized, placebo-controlled trial, carbetocin showed no difference from placebo for hyperphagia after 12 weeks.
A review of current and upcoming drug options for weight in PWS.
Among 77 people in the long-term extension, those who restarted after a 16-week placebo withdrawal improved on the hyperphagia score by week 13 (−4.5) and further at two years (−6.3), with stable BMI.
Approval for hyperphagia in people 4 and older with PWS, the first drug for it. The Phase 3 trial missed its primary endpoint overall but showed benefit in severe hyperphagia, with a 16-week withdrawal that favored continuing treatment.
At the 3.2 mg dose, carbetocin reduced hyperphagia and anxiety in ages 7–18.
One drug is approved for hunger. Growth hormone, structured food environments, therapies and hormone care make up the rest of care.
An extended-release tablet. The Phase 3 trial (127 people) missed its main goal overall but helped those with severe hunger. Common side effects are excess hair growth, swelling and high blood sugar, so blood sugar must be monitored.
Improvements in hunger and behavior held for two years, and BMI stayed stable in those who restarted treatment after the placebo period.
Improves growth, muscle and body composition, and is part of standard care in many countries.
An oxytocin-like spray. CARE-PWS reported benefit in ages 7–18. The later COMPASS PWS trial found no difference from placebo at 12 weeks.
Locked or controlled food access, scheduled meals and consistent routines are the foundation of weight and behavior care.
Starting in infancy builds muscle strength, feeding and communication skills.
| Treatment | For | What it does |
|---|---|---|
| Diazoxide choline (Vykat XR) | Hyperphagia, ages 4+ | Reduces hunger and related behavior. Needs blood-sugar monitoring. |
| Growth hormone | Children and some adults | Supports growth, muscle and lower body fat. |
| Sex-hormone care | Adolescents and adults | Replaces low hormones when needed. |
| Dietitian-led plan & food security | Everyone | Controls calories and access to food. |
| Sleep, scoliosis & mental health care | As needed | Treats common related problems. |
No supplement stops PWS hunger. The most effective daily tools are about the environment. We rate each by the strength of evidence.
Locks, supervision and consistent meal times are the most reliable way to prevent obesity.
Regular movement supports muscle and weight.
Structure reduces anxiety and behavior outbursts for many people.
Unproven in PWS and may be unsafe. Check with the care team first.
People with PWS need a dietitian-led plan, because needs differ from the general population.
The hunger is neurological. Environmental control works better than appeals to self-control.
Be careful: people with PWS can have a high pain tolerance and may not show fever or vomiting normally. Treat unexplained illness seriously and see a doctor.
Centers recognized for expertise in this condition, and communities of people living with it.
Says it has cared for more than 220 people with PWS and took part in the pivotal study behind the first FDA-approved hyperphagia treatment for PWS.
Runs the Multidisciplinary Prader-Willi Wellness, Education and Research Center, a team program for people with PWS.
A team clinic for PWS that also lists a Vanderbilt physician in the Foundation for Prader-Willi Research's clinic network.
A listed site in a registered Phase 3 trial of DCCR in Prader-Willi syndrome and a member of the PWS-CLIC network.
Coordinates France's national rare-disease reference center for Prader-Willi syndrome, a role it has held since 2004.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Caring for someone with PWS is demanding, and other families understand. Most of these are free.
The national U.S. organization for people with PWS, offering family support, information and events.
Visit ↗Funds research and shares research and clinical-trial news for families.
Visit ↗Connects national PWS associations and families worldwide.
Visit ↗Many private parent and caregiver groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Growth hormone and structured care are used across many countries. Vykat XR is the only drug approved for hunger that we verified, and only in the U.S.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Diazoxide choline (Vykat XR)Hyperphagia | Approved 2025 | — | — | — | — | — | — | — | — |
| Growth hormone for PWSStandard care | Used | Used | — | — | — | — | — | — | — |
A pivotal Phase 3 study of carbetocin ran across sites and reported no benefit over placebo in 2026.
The earlier CARE-PWS trial reported reduced hyperphagia and anxiety in children and teens at one dose.
Researchers worldwide are studying hormone and brain-signaling approaches, summarized in an experimental-therapies overview.
PWS happens when a region of chromosome 15 inherited from the father (15q11-q13) is missing or switched off. Several genes there are normally active only on the father's copy, so nothing replaces them.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These regional organizations help families affected by Prader-Willi syndrome pay for care and costs. Funds are limited and rules vary, so contact each one directly.
A volunteer-run nonprofit that gives grants toward medical treatment costs, travel to conferences, social work and similar needs. Applicants request an amount through an online form; no deadline or maximum is stated.
See services ↗Gives direct grants to families to help with respite care, summer camps, community activities and items such as iPads and adaptive bikes. Its board reviews grant requests monthly.
Learn more ↗Members can get one free set of fridge locks to help keep food safe at home. A small donation is suggested but not required.
See the program ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
Not individually cited: the cause (paternal chromosome 15q11-q13 loss or maternal disomy), the incidence, the Angelman mirror condition, the 1956 and 1981 history dates, growth hormone as standard care, and the lower oxytocin-neuron count, which reflect the established medical literature. The "Used" entries for growth hormone and all "—" cells in the approvals table are unverified. Whether Vykat XR's maker is now Neurocrine Biosciences is based on the company's own release hosting. Confirm before relying on it. Expert care centers: No official center-of-excellence designation exists for Prader-Willi syndrome that could be verified, so these are listed for clinic programs, network membership or trial roles. The Cook Children's entry rests on its own page. Financial help: checked October 6, 2026. No national U.S. program giving families direct financial aid for PWS was found; PWSA | USA's 2027 convention scholarship was left out because it pays for conference attendance and closed June 1, 2026. The Colorado association's pages block automated checks and were read with a headless browser. The Utah association's grant guidance gives no deadline and no separate family grant size.